Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,634 SEK | -1.21% | -0.73% | +20.72% |
May. 03 | Angle shares up on assay development deal with AstraZeneca | AN |
May. 03 | Angle shares up on assay development deal with AstraZenaca | AN |
Sales 2024 * | 51.18B 553B | Sales 2025 * | 54.8B 593B | Capitalization | 234B 2,536B |
---|---|---|---|---|---|
Net income 2024 * | 8.52B 92.13B | Net income 2025 * | 10.19B 110B | EV / Sales 2024 * | 4.97 x |
Net Debt 2024 * | 20.03B 217B | Net Debt 2025 * | 13.54B 146B | EV / Sales 2025 * | 4.52 x |
P/E ratio 2024 * |
27.9
x | P/E ratio 2025 * |
23.3
x | Employees | 89,900 |
Yield 2024 * |
2.05% | Yield 2025 * |
2.14% | Free-Float | 96.5% |
Latest transcript on AstraZeneca PLC
1 day | -1.21% | ||
1 week | -0.73% | ||
Current month | -2.24% | ||
1 month | +13.20% | ||
3 months | +18.41% | ||
6 months | +15.89% | ||
Current year | +20.72% |
Managers | Title | Age | Since |
---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 17-09-30 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 13-01-31 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 1,634 | -1.21% | 230,936 |
24-05-02 | 1,654 | -1.05% | 338,332 |
24-04-30 | 1,672 | +0.97% | 124,463 |
24-04-29 | 1,656 | +0.58% | 292,246 |
24-04-26 | 1,646 | +0.27% | 316,442 |
Delayed Quote Nasdaq Stockholm, May 03, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B | |
-3.40% | 157B | |
+1.72% | 123B |
- Stock Market
- Equities
- AZN Stock
- AZN Stock